Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain
Authors
Affiliations
N,N-dimethyltryptamine (DMT), a psychedelic compound identified endogenously in mammals, is biosynthesized by aromatic-L-amino acid decarboxylase (AADC) and indolethylamine-N-methyltransferase (INMT). Whether DMT is biosynthesized in the mammalian brain is unknown. We investigated brain expression of INMT transcript in rats and humans, co-expression of INMT and AADC mRNA in rat brain and periphery, and brain concentrations of DMT in rats. INMT transcripts were identified in the cerebral cortex, pineal gland, and choroid plexus of both rats and humans via in situ hybridization. Notably, INMT mRNA was colocalized with AADC transcript in rat brain tissues, in contrast to rat peripheral tissues where there existed little overlapping expression of INMT with AADC transcripts. Additionally, extracellular concentrations of DMT in the cerebral cortex of normal behaving rats, with or without the pineal gland, were similar to those of canonical monoamine neurotransmitters including serotonin. A significant increase of DMT levels in the rat visual cortex was observed following induction of experimental cardiac arrest, a finding independent of an intact pineal gland. These results show for the first time that the rat brain is capable of synthesizing and releasing DMT at concentrations comparable to known monoamine neurotransmitters and raise the possibility that this phenomenon may occur similarly in human brains.
Chaves C, Dos Santos R, Dursun S, Tusconi M, Carta M, Brietzke E Front Psychiatry. 2024; 15:1485337.
PMID: 39568756 PMC: 11576444. DOI: 10.3389/fpsyt.2024.1485337.
Egger K, Aicher H, Cumming P, Scheidegger M Cell Mol Life Sci. 2024; 81(1):395.
PMID: 39254764 PMC: 11387584. DOI: 10.1007/s00018-024-05353-6.
Within-subject comparison of near-death and psychedelic experiences: acute and enduring effects.
Martial C, Carhart-Harris R, Timmermann C Neurosci Conscious. 2024; 2024(1):niae033.
PMID: 39220326 PMC: 11363954. DOI: 10.1093/nc/niae033.
Gomez-Escolar A, Folch-Sanchez D, Stefaniuk J, Swithenbank Z, Nisa A, Braddick F CNS Drugs. 2024; 38(10):771-789.
PMID: 39033264 DOI: 10.1007/s40263-024-01101-3.
Psychotomimetic compensation versus sensitization.
Brouwer A, Carhart-Harris R, Raison C Pharmacol Res Perspect. 2024; 12(4):e1217.
PMID: 38923845 PMC: 11194300. DOI: 10.1002/prp2.1217.